ARTICLE | Clinical News
KD025: Phase II started
September 26, 2016 7:00 AM UTC
Kadmon began a double-blind, U.S. Phase II trial to evaluate oral KD025 for 16 weeks in about 150 patients. Patients will receive 200 mg KD025 once or twice daily; 400 mg KD025 once daily; 400 mg KD02...